SLC2A1 and chronic kidney disease: Although ghrelin and leptin changes during cKD are of great interest due to their impact on the nutritional and metabolic outcomes of cKD and their potential effects as therapeutic targets in neurological diseases [30], to the best of our knowledge they have been analysed several times in DRE and GLUT1-DS [19,20,21], where the cKD must be followed for long term, but it is difficult to draw substantial conclusions due to short follow-up examinations or incomplete data.